论文部分内容阅读
经过目前标准的治疗方案治疗后,慢性丙型肝炎(丙肝)合并肝硬化的患者疗效不佳。随着治疗丙肝新药越来越多,许多新的治疗慢性丙肝合并肝硬化的抗病毒方案出现了。由于第一代蛋白酶抑制药博赛匹韦、特拉匹韦的不良反应较大,因此用于丙肝合并肝硬化患者的治疗需要谨慎。其他治疗丙肝的新药辛姆匹韦、索非布韦、来第帕韦对于丙肝合并代偿性硬肝化患者有疗效,但是有合并症患者的病毒应答(SVR)低于没有合并症的患者。因此,今后需要优化这些药物组合的治疗方案,以此缩小持续性的病毒应答的差距。
After the current standard treatment regimen, patients with chronic hepatitis C (HCV) and cirrhosis have poor outcomes. With the increasing availability of new drugs for hepatitis C, many new antiviral strategies for the treatment of chronic hepatitis C with cirrhosis have emerged. Because of the adverse effects of the first generation protease inhibitor, beta-prophylaxis and verapamil, caution should be exercised in the treatment of hepatitis C patients with cirrhosis. Other new drugs for the treatment of hepatitis C, cemedimir, sofosbuvir and dipyridamole, are effective in patients with hepatitis C complicated with compensated cirrhosis, but those with comorbidity have lower SVR than those without complications . Therefore, the future need to optimize the treatment of these drug combinations, in order to narrow the gap between persistent viral response.